ALFA Finder| Management target | Revenue 107.0% FY30 |
|---|
| Revenue growth | ₹489.7 Cr vs ₹170.8 Cr YoY. |
|---|---|
| Margins | Q1 FY27 EBITDA margin at 9.9% vs 12.9% in Q4 FY26. |
| Order book | Secured integrated animal waste management contract from BBMP/BSWML. |
| Demand visibility | Strong domestic and export demand across 25+ countries. |
| Management confidence | High; citing multi-year growth driven by integration and expansion. |
Growth
Revenue grew significantly to ₹489.7 Cr in Q1 FY27 from ₹170.8 Cr in Q1 FY26. EBITDA reached ₹48.6 Cr.
Outlook
Targeting over 2x revenue growth in ~4 years (₹3,000+ Cr by FY30). Upcoming Oman facility expanding production capacity.
Risks
Supply constraints in fishmeal expected globally by 2028; climate change (El Niño) impacting raw material availability.
Investor Presentation filed with NSE, NSE: MUKKA. Summary written with AI assistance from the document.
Mukka Proteins Ltd: key numbers
- Share price
- ₹26.61
- Market cap
- ₹798.3 Cr
- Revenue (annual)
- ₹1,449 Cr
- Net profit (annual)
- ₹52.06 Cr
- P/E (TTM)
- 10.1×Sector 29.0×
- Promoter holding
- 73.33%+0.00% QoQ
- FII holding
- 1.70%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Mukka Proteins Ltd
All →Mukka Proteins Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹508.9 Cr (+108% YoY), EBITDA ₹50.1 Cr (9.9% margin), PAT ₹17.7 Cr (3.5%). Targets ₹3,000+ Cr revenue by FY30.
Mukka Proteins Results Update
Mukka Proteins reported Q2 FY27 revenue up 108% YoY to Rs.5,088.70 Mn. The Oman facility began commercial production, adding 37,200 MTPA of capacity.
- Oman facility manufacturing capacity
- 37200.0 MTPA
Mukka Proteins Acquisition Worth ₹2.13 Cr
Mukka Proteins' board approved revised terms to acquire 85,200 equity shares, a 46% stake, in Swachha Eco Solutions for up to Rs 2.13 Crore. The unlisted waste-management company is not a related party.
- Value
- ₹2.13 Cr
- Execution
- Up to 31-03-2027
Mukka Proteins Other Announcement
Mukka Proteins filed its quarterly statement of deviation for funds raised through a preferential warrant issue, reporting no deviation. Utilisation of Rs. 11.75 Crore against the working capital object is shown for the quarter ended September 2026.
Mukka Proteins Q2 FY27 Results: Net Profit ₹17.7 Cr, Up 156.5% YoY
Mukka Proteins Ltd reported revenue from operations of ₹508.9 Cr (+108.1% YoY) and net profit of ₹17.7 Cr (+156.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹17.7 Cr · +156.5% YoY
Mukka Proteins Board Meeting Date
Mukka Proteins intimated a board meeting on 07 Nov 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window closure is also disclosed.